Netherlands: These 7 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 29, 2023
Generic Entry Controlled by: Netherlands Patent 300,918

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Netherlands Patent 300,933

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Netherlands Patent 300,913

VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Netherlands Patent 300,812

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: lomitapide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: Netherlands Patent 300,634

JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Netherlands Patent 300,694

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Netherlands Patent 1,028,967
Patent Title: 4-Fenylamino-chinazoline-6-yl-amiden.

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.